Literature DB >> 26526358

A small molecule neutrophil elastase inhibitor, KRP-109, inhibits cystic fibrosis mucin degradation.

Shashi Chillappagari1, Christian Müller2, Poornima Mahavadi3, Andreas Guenther4, Lutz Nährlich5, Jonathan Rosenblum6, Bruce K Rubin7, Markus O Henke8.   

Abstract

BACKGROUND: Neutrophil elastase (NE) rapidly degrades gel-forming airway mucins in cystic fibrosis (CF) sputum. We hypothesized that KRP-109, a small molecule NE inhibitor, would inhibit CF mucin degradation in vitro.
METHODS: Sputa were collected from CF patients (n=5) chronically or intermittently infected with Pseudomonas aeruginosa (P.a.). Mucin degradation was analyzed using western blot. Protease inhibitor studies were performed using alpha1-proteinase inhibitor (A1-PI Prolastin®) and KRP-109. Elastase activity assays were performed using spectrophotometry.
RESULTS: There were significant differences in the amount of active NE in different CF sputum samples. KRP-109 decreased the NE driven mucin degradation in vitro. Pseudomonas elastases appeared to blunt elastase inhibition by A1-PI or KRP-109.
CONCLUSION: Inhibitors of neutrophil and Pseudomonas-derived elastases might rescue mucus clearance and reverse airway obstruction in CF.
Copyright © 2015 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cystic fibrosis; Mucin; Protease and anti-protease balance; Small molecule inhibitors

Mesh:

Substances:

Year:  2015        PMID: 26526358     DOI: 10.1016/j.jcf.2015.10.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  5 in total

Review 1.  ERS International Congress 2021: highlights from the Respiratory Infections Assembly.

Authors:  Oliver W Meldrum; Kylie B R Belchamber; Kiarina D Chichirelo-Konstantynovych; Katie L Horton; Tetyana V Konstantynovych; Merete B Long; Melissa J McDonnell; Lidia Perea; Alberto L Garcia-Basteiro; Michael R Loebinger; Raquel Duarte; Holly R Keir
Journal:  ERJ Open Res       Date:  2022-05-23

Review 2.  Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease.

Authors:  Jing Sun; Xiao Shen; Yi Li; Zhen Guo; Weiming Zhu; Lugen Zuo; Jie Zhao; Lili Gu; Jianfeng Gong; Jieshou Li
Journal:  Nutrients       Date:  2016-01-14       Impact factor: 5.717

Review 3.  Proteases Revisited: Roles and Therapeutic Implications in Fibrosis.

Authors:  Jakub Kryczka; Joanna Boncela
Journal:  Mediators Inflamm       Date:  2017-05-31       Impact factor: 4.711

Review 4.  Alpha-1 Antitrypsin-A Target for MicroRNA-Based Therapeutic Development for Cystic Fibrosis.

Authors:  Alison M D Hunt; Arlene M A Glasgow; Hilary Humphreys; Catherine M Greene
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

Review 5.  Immunomodulation in Cystic Fibrosis: Why and How?

Authors:  Vincent D Giacalone; Brian S Dobosh; Amit Gaggar; Rabindra Tirouvanziam; Camilla Margaroli
Journal:  Int J Mol Sci       Date:  2020-05-08       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.